Syed Osman, Jancic Predrag, Fink Adam B, Knezevic Nebojsa Nick
Advocate Illinois Masonic Medical Center, Department of Anesthesiology, Chicago, IL 60657, USA.
Chicago College of Osteopathic Medicine, Midwestern University, Downers Grove, IL 60515, USA.
Pharmaceuticals (Basel). 2023 Oct 20;16(10):1497. doi: 10.3390/ph16101497.
Chronic pain is one of the main leading causes of disability in the world at present. A variety in the symptomatology, intensity and duration of this phenomenon has led to an ever-increasing demand of pharmacological treatment and relief. This demand for medication, ranging from well-known groups, such as antidepressants and benzodiazepines, to more novel drugs, was followed by a rise in safety concerns of such treatment options. The validity, frequency, and diversity of such concerns are discussed in this paper, as well as their possible effect on future prescription practices. A specific caution is provided towards the psychological safety and toll of these medications, regarding suicidality and suicidal ideation. Most significantly, this paper highlights the importance of pharmacovigilance and underscores the necessity of surveillance programs when considering chronic pain medication.
慢性疼痛是目前全球致残的主要原因之一。这种现象在症状学、强度和持续时间上的多样性导致了对药物治疗和缓解的需求不断增加。从抗抑郁药和苯二氮䓬类等知名药物类别到更新的药物，对药物的这种需求伴随着对这些治疗选择安全性担忧的增加。本文讨论了这些担忧的有效性、频率和多样性，以及它们对未来处方实践可能产生的影响。针对这些药物对心理安全的影响以及自杀倾向和自杀念头，提出了特别的警示。最重要的是，本文强调了药物警戒的重要性，并强调了在考虑慢性疼痛药物时监测计划的必要性。
